Seyed Reza Taha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seyed Reza Taha has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Fouad Boulos
Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
7 shared publications - Andarz Fazlollahpour Naghibi
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
2 shared publications - Kimia Bagheri
Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
2 shared publications - Mahdieh Shariat Zadeh
Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
2 shared publications Ajay Kumar
Institute of Aerospace Medicine & Command Hospital, Bangalore, India
1 shared publication- Ali Rostami
Babol University of Medical Sciences
1 shared publication
Latest Publications
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (2) , e2500974
Prognostic Significance of Isolated Tumor Cells and the Role of Immunohistochemistry in Nodal Evaluation in Breast Cancer: A SEER-Based Analysis and Reappraisal
PURPOSE: The prognostic significance of isolated tumor cells (ITCs) in lymph nodes remains uncertain, and immunohistochemistry (IHC) is not consistently used for their detection. We aimed to evaluate the clinical relevance of ITCs and assess whether omission of IHC leads to nodal understaging by comparing outcomes across node-negative patients with and without IHC-confirmed negativity. MATERIALS AND METHODS: In this retrospective population-based cohort study, we analyzed SEER data from 2010 to 2015, including 127,494 women with invasive breast cancer. Nodal status was classified as N0, N0(i–), N0(i+), or N1mi. Breast cancer–specific survival (BCSS) was evaluated using univariable and multivariable Fine-Gray competing risk regression. Overall survival (OS) was assessed using univariable and multivariable flexible parametric survival models (FPSMs). Models were adjusted for age, tumor grade, histologic subtype, estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 status, T stage, race, surgery, chemotherapy, radiation, marital status, number of lymph nodes examined, and year of diagnosis. Subgroup analysis was performed among patients who received both chemotherapy and radiation. RESULTS: Compared with N0(i–), both N0(i+) and N0 were significantly associated with worse BCSS (adjusted subdistribution hazard ratio [SHR], 1.40 [95% CI, 1.23 to 1.60]; P < .001 and 1.09 [95% CI, 1.03 to 1.16]; P = .003, respectively). N0(i+) also had worse BCSS than N0 (adjusted SHR, 1.28 [95% CI, 1.13 to 1.46]; P < .001). For OS, N0(i+) and N0 showed higher mortality risks compared with N0(i–) in the multivariable FPSM (HR, 1.15 [95% CI, 1.06 to 1.25]; P = .001 and 1.10 [95% CI, 1.07 to 1.14]; P < .001, respectively), with no significant difference between N0(i+) and N0 (HR, 1.05 [95% CI, 0.97 to 1.13]; P = .26). In patients receiving both chemotherapy and radiation, N0(i+), compared with N0(i–), remained associated with worse OS (HR, 1.26 [95% CI, 1.02 to 1.56]; P = .03), whereas BCSS differences were not statistically significant. CONCLUSION: ITCs are associated with worse BCSS and OS despite classification as node-negative. Omitting IHC may obscure their detection. Incorporating IHC into routine nodal evaluation may enhance prognostic assessment and guide treatment decisions.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (2) , e2500974
Prognostic Significance of Isolated Tumor Cells and the Role of Immunohistochemistry in Nodal Evaluation in Breast Cancer: A SEER-Based Analysis and Reappraisal
PURPOSE: The prognostic significance of isolated tumor cells (ITCs) in lymph nodes remains uncertain, and immunohistochemistry (IHC) is not consistently used for their detection. We aimed to evaluate the clinical relevance of ITCs and assess whether omission of IHC leads to nodal understaging by comparing outcomes across node-negative patients with and without IHC-confirmed negativity. MATERIALS AND METHODS: In this retrospective population-based cohort study, we analyzed SEER data from 2010 to 2015, including 127,494 women with invasive breast cancer. Nodal status was classified as N0, N0(i–), N0(i+), or N1mi. Breast cancer–specific survival (BCSS) was evaluated using univariable and multivariable Fine-Gray competing risk regression. Overall survival (OS) was assessed using univariable and multivariable flexible parametric survival models (FPSMs). Models were adjusted for age, tumor grade, histologic subtype, estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 status, T stage, race, surgery, chemotherapy, radiation, marital status, number of lymph nodes examined, and year of diagnosis. Subgroup analysis was performed among patients who received both chemotherapy and radiation. RESULTS: Compared with N0(i–), both N0(i+) and N0 were significantly associated with worse BCSS (adjusted subdistribution hazard ratio [SHR], 1.40 [95% CI, 1.23 to 1.60]; P < .001 and 1.09 [95% CI, 1.03 to 1.16]; P = .003, respectively). N0(i+) also had worse BCSS than N0 (adjusted SHR, 1.28 [95% CI, 1.13 to 1.46]; P < .001). For OS, N0(i+) and N0 showed higher mortality risks compared with N0(i–) in the multivariable FPSM (HR, 1.15 [95% CI, 1.06 to 1.25]; P = .001 and 1.10 [95% CI, 1.07 to 1.14]; P < .001, respectively), with no significant difference between N0(i+) and N0 (HR, 1.05 [95% CI, 0.97 to 1.13]; P = .26). In patients receiving both chemotherapy and radiation, N0(i+), compared with N0(i–), remained associated with worse OS (HR, 1.26 [95% CI, 1.02 to 1.56]; P = .03), whereas BCSS differences were not statistically significant. CONCLUSION: ITCs are associated with worse BCSS and OS despite classification as node-negative. Omitting IHC may obscure their detection. Incorporating IHC into routine nodal evaluation may enhance prognostic assessment and guide treatment decisions.
- 13 July 2025
- Published by SAGE Publications in Wilderness & Environmental Medicine
Space Oncology: A Comprehensive Scoping Review
Space exploration exposes astronauts to unique conditions such as microgravity and space radiation, potentially influencing gene expression and triggering carcinogenesis. Paradoxically, these extreme environments could uncover other pro-treatment aspects of cancer biology. Despite numerous reviews addressing these aspects in isolation, a comprehensive synthesis of the effects of space stressors on cancer development is incomplete. This scoping review aims to provide a holistic perspective on the influence of spaceflight and associated stressors—including gravitation (hyper- and microgravity), radiation, and vibration—on the potential for cancer development and altered cellular mechanisms. We adhered to the PRISMA-ScR checklist for our review. A multitiered search strategy was employed in English, starting with a preliminary keyword identification in Google Scholar and PubMed. Subsequently, the main search was conducted across five databases—Cochrane, Embase, PubMed, Scopus, and Web of Science—until 22 February 2024. All included studies were thoroughly assessed by two independent reviewers. Of the 15,553 identified articles, 158 were deemed eligible. The majority (92%) were experimental studies, predominantly cell-based (74.17%). Breast (15.19%), thyroid (13.92%), and hematopoietic (11.40%) cancers were the most frequently examined. Spaceflight stressors could affect different biological systems variably, with microgravity impacting spatial growth and metastasis, and cosmic radiation exerting both tumor-suppressive and mutagenic effects. Our findings highlight the need for large-scale, prolonged analog studies mimicking space conditions to enhance mission safety and shed light on the nuanced effects of space stressors on cancer. Additionally, further extensive studies need to be performed in the true weightlessness of spaceflight, both animal-based and on human tissue (cell cultures and potentially whole perfusion organ models), in addition to crew pre/intra/post-flight long-duration evaluations. Furthermore, this unique research avenue may reveal cancer cell sensitivities to these stressors, opening new pathways for innovative therapeutic strategies in cancer treatment.
- 13 July 2025
- Published by SAGE Publications in Wilderness & Environmental Medicine
Space Oncology: A Comprehensive Scoping Review
Space exploration exposes astronauts to unique conditions such as microgravity and space radiation, potentially influencing gene expression and triggering carcinogenesis. Paradoxically, these extreme environments could uncover other pro-treatment aspects of cancer biology. Despite numerous reviews addressing these aspects in isolation, a comprehensive synthesis of the effects of space stressors on cancer development is incomplete. This scoping review aims to provide a holistic perspective on the influence of spaceflight and associated stressors—including gravitation (hyper- and microgravity), radiation, and vibration—on the potential for cancer development and altered cellular mechanisms. We adhered to the PRISMA-ScR checklist for our review. A multitiered search strategy was employed in English, starting with a preliminary keyword identification in Google Scholar and PubMed. Subsequently, the main search was conducted across five databases—Cochrane, Embase, PubMed, Scopus, and Web of Science—until 22 February 2024. All included studies were thoroughly assessed by two independent reviewers. Of the 15,553 identified articles, 158 were deemed eligible. The majority (92%) were experimental studies, predominantly cell-based (74.17%). Breast (15.19%), thyroid (13.92%), and hematopoietic (11.40%) cancers were the most frequently examined. Spaceflight stressors could affect different biological systems variably, with microgravity impacting spatial growth and metastasis, and cosmic radiation exerting both tumor-suppressive and mutagenic effects. Our findings highlight the need for large-scale, prolonged analog studies mimicking space conditions to enhance mission safety and shed light on the nuanced effects of space stressors on cancer. Additionally, further extensive studies need to be performed in the true weightlessness of spaceflight, both animal-based and on human tissue (cell cultures and potentially whole perfusion organ models), in addition to crew pre/intra/post-flight long-duration evaluations. Furthermore, this unique research avenue may reveal cancer cell sensitivities to these stressors, opening new pathways for innovative therapeutic strategies in cancer treatment.
- 28 May 2025
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 33 (4) , 204-210
The Value of Routine Reflex In Situ Hybridization Testing in Low-grade Tubule-forming Invasive Breast Cancers With Equivocal HER2 Immunohistochemistry
Guidelines from the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) recommend an equivocal score (2+) and reflex in situ hybridization (ISH) testing for invasive breast cancer (IBC) with moderate to strong lateral or basolateral staining by HER2 immunohistochemistry (IHC). While this recommendation mainly addresses aggressive tumor types such as micropapillary carcinoma, it is applied to low-grade, tubule-forming IBCs unlikely to show HER2 amplification. A total of 62 cases of IBC with equivocal HER2 IHC, low histologic grade (1/3), and tubule formation scores of 1 or 2 according to Nottingham criteria were retrospectively identified from 2020 to 2023 to determine the frequency of HER2 amplification using fluorescent ISH (FISH). Following slide review, 3 cases were reclassified as grade 2, leaving 59 cases for analysis. Demographic and clinicopathological data were collected from medical records and analyzed. A total of 98.3% of cases were not amplified by HER2 FISH, with only 1 case showing amplification. All cases were ER positive. Oncotype DX scores, available for select cases, showed low recurrence scores (below 25). The single HER2-amplified case contained a ductal carcinoma in situ component with HER2 3+ staining, potentially leading to a false positive result. In conclusion, HER2 amplification is rare in low-grade, tubule-forming IBCs. These results suggest reconsidering current guidelines to reduce unnecessary FISH testing, potentially improving cost-effectiveness and clinical efficiency without compromising diagnostic accuracy.
- 28 May 2025
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 33 (4) , 204-210
The Value of Routine Reflex In Situ Hybridization Testing in Low-grade Tubule-forming Invasive Breast Cancers With Equivocal HER2 Immunohistochemistry
Guidelines from the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) recommend an equivocal score (2+) and reflex in situ hybridization (ISH) testing for invasive breast cancer (IBC) with moderate to strong lateral or basolateral staining by HER2 immunohistochemistry (IHC). While this recommendation mainly addresses aggressive tumor types such as micropapillary carcinoma, it is applied to low-grade, tubule-forming IBCs unlikely to show HER2 amplification. A total of 62 cases of IBC with equivocal HER2 IHC, low histologic grade (1/3), and tubule formation scores of 1 or 2 according to Nottingham criteria were retrospectively identified from 2020 to 2023 to determine the frequency of HER2 amplification using fluorescent ISH (FISH). Following slide review, 3 cases were reclassified as grade 2, leaving 59 cases for analysis. Demographic and clinicopathological data were collected from medical records and analyzed. A total of 98.3% of cases were not amplified by HER2 FISH, with only 1 case showing amplification. All cases were ER positive. Oncotype DX scores, available for select cases, showed low recurrence scores (below 25). The single HER2-amplified case contained a ductal carcinoma in situ component with HER2 3+ staining, potentially leading to a false positive result. In conclusion, HER2 amplification is rare in low-grade, tubule-forming IBCs. These results suggest reconsidering current guidelines to reduce unnecessary FISH testing, potentially improving cost-effectiveness and clinical efficiency without compromising diagnostic accuracy.
- 16 May 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (8) , 1801-1806
Morphologically In Situ Solid Papillary Carcinoma of the Breast With Lymph Node and Lung Metastasis: A Rare Case Report and Literature Review
Solid papillary carcinoma (SPC) is rare, accounting for less than 1% of all breast cancers. According to the 5th edition of the WHO Classification of Breast Tumors (2019), SPC is divided into invasive (ISPC) and in situ (SPC in situ) subtypes. ISPC is characterized by an irregular or jigsaw pattern lacking myoepithelial cells, while SPC in situ is well-circumscribed, regardless of myoepithelial cell presence. Metastasis is infrequently reported, with most patients involving lymph nodes and arising from ISPC. Metastases from SPC in situ without myoepithelial cells have rarely been reported. We present a 66-year-old woman with a 28 × 13 mm hypoechoic breast mass detected on ultrasound. Microscopic examination revealed well-circumscribed nests of SPC, positive for ER, PR, and synaptophysin, with a Ki-67 proliferation index of 10%. HER2 was negative. Myoepithelial markers, including p63, smooth muscle actin, keratin 5/6, p40, and CD10, were all negative, confirming the absence of a myoepithelial layer. Axillary lymph node dissection revealed metastasis in three of eighteen lymph nodes, with the metastatic foci demonstrating the same well-circumscribed SPC architecture as the primary tumor in the breast. Additionally, a lung biopsy exhibited metastatic SPC with identical histomorphology and immunohistochemical profile to the primary tumor. Although rare, SPC presenting a well-circumscribed morphology, and classified as in situ according to the WHO, should be approached with caution when myoepithelial cells are absent, as the in situ histomorphology does not necessarily exclude the potential for metastasis.
- 16 May 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (8) , 1801-1806
Morphologically In Situ Solid Papillary Carcinoma of the Breast With Lymph Node and Lung Metastasis: A Rare Case Report and Literature Review
Solid papillary carcinoma (SPC) is rare, accounting for less than 1% of all breast cancers. According to the 5th edition of the WHO Classification of Breast Tumors (2019), SPC is divided into invasive (ISPC) and in situ (SPC in situ) subtypes. ISPC is characterized by an irregular or jigsaw pattern lacking myoepithelial cells, while SPC in situ is well-circumscribed, regardless of myoepithelial cell presence. Metastasis is infrequently reported, with most patients involving lymph nodes and arising from ISPC. Metastases from SPC in situ without myoepithelial cells have rarely been reported. We present a 66-year-old woman with a 28 × 13 mm hypoechoic breast mass detected on ultrasound. Microscopic examination revealed well-circumscribed nests of SPC, positive for ER, PR, and synaptophysin, with a Ki-67 proliferation index of 10%. HER2 was negative. Myoepithelial markers, including p63, smooth muscle actin, keratin 5/6, p40, and CD10, were all negative, confirming the absence of a myoepithelial layer. Axillary lymph node dissection revealed metastasis in three of eighteen lymph nodes, with the metastatic foci demonstrating the same well-circumscribed SPC architecture as the primary tumor in the breast. Additionally, a lung biopsy exhibited metastatic SPC with identical histomorphology and immunohistochemical profile to the primary tumor. Although rare, SPC presenting a well-circumscribed morphology, and classified as in situ according to the WHO, should be approached with caution when myoepithelial cells are absent, as the in situ histomorphology does not necessarily exclude the potential for metastasis.
- 1 May 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 26 (7) , 957-971
The Hepatoprotective Effects of Ginsenoside from Ginseng: A Review of Molecular Mechanisms and Therapeutic Potentials
Treatment of hepatic diseases presents a significant challenge due to their diverse nature. Ginsenosides, bioactive compounds derived from the root of Panax ginseng and widely used in traditional Chinese medicine, offer multifaceted protection to various organs in the body. Their versatile effects, including antioxidant, anti-inflammatory, anti-apoptotic and more, make them a promising approach for addressing hepatic disorders. This review explores the intricate molecular mechanisms and properties of ginsenosides in the prevention and treatment of liver ailments, from mild conditions to severe damage and liver fibrosis. Given the increasing prevalence of hepatic disorders, this article sheds light on the significant pharmaceutical potential of ginsenosides in the realm of hepatic disease management.
- 1 May 2025
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 26 (7) , 957-971
The Hepatoprotective Effects of Ginsenoside from Ginseng: A Review of Molecular Mechanisms and Therapeutic Potentials
Treatment of hepatic diseases presents a significant challenge due to their diverse nature. Ginsenosides, bioactive compounds derived from the root of Panax ginseng and widely used in traditional Chinese medicine, offer multifaceted protection to various organs in the body. Their versatile effects, including antioxidant, anti-inflammatory, anti-apoptotic and more, make them a promising approach for addressing hepatic disorders. This review explores the intricate molecular mechanisms and properties of ginsenosides in the prevention and treatment of liver ailments, from mild conditions to severe damage and liver fibrosis. Given the increasing prevalence of hepatic disorders, this article sheds light on the significant pharmaceutical potential of ginsenosides in the realm of hepatic disease management.
- 5 March 2025
- Published by BMJ in Journal of Clinical Pathology
- Vol. 78 (6) , 361-363
Re-evaluating the relevance of extensive intraductal component (EIC) in modern breast cancer management
The concept of extensive intraductal component (EIC), currently defined by the presence of a prominent ductal carcinoma in situ (DCIS) component within an invasive tumor and extending beyond its margins, was introduced in the 1980s as a predictor of local recurrence following breast-conserving therapy for invasive breast carcinoma. At the time, surgical excision to negative margins was not the standard of care, making EIC a valuable tool for identifying patients at risk of recurrence. However, with modern oncologic and surgical advancements, its clinical relevance has diminished. Despite its continued inclusion as a mandatory entry in the CAP synoptic checklist, studies have shown that EIC does not independently predict local recurrence when margins are negative. Instead, objective parameters such as DCIS size and nuclear grade more accurately correlate with margin status and recurrence risk. While EIC may still be useful in preoperative biopsy assessments for evaluating disease extent among other things, its routine reporting in resection specimens appears less informative. Given its vague definition and limited prognostic value, we propose that EIC reporting should be discretionary rather than mandatory, with emphasis placed on more objective and clinically relevant metrics.
- 5 March 2025
- Published by BMJ in Journal of Clinical Pathology
- Vol. 78 (6) , 361-363
Re-evaluating the relevance of extensive intraductal component (EIC) in modern breast cancer management
The concept of extensive intraductal component (EIC), currently defined by the presence of a prominent ductal carcinoma in situ (DCIS) component within an invasive tumor and extending beyond its margins, was introduced in the 1980s as a predictor of local recurrence following breast-conserving therapy for invasive breast carcinoma. At the time, surgical excision to negative margins was not the standard of care, making EIC a valuable tool for identifying patients at risk of recurrence. However, with modern oncologic and surgical advancements, its clinical relevance has diminished. Despite its continued inclusion as a mandatory entry in the CAP synoptic checklist, studies have shown that EIC does not independently predict local recurrence when margins are negative. Instead, objective parameters such as DCIS size and nuclear grade more accurately correlate with margin status and recurrence risk. While EIC may still be useful in preoperative biopsy assessments for evaluating disease extent among other things, its routine reporting in resection specimens appears less informative. Given its vague definition and limited prognostic value, we propose that EIC reporting should be discretionary rather than mandatory, with emphasis placed on more objective and clinically relevant metrics.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Hematology
- Vol. 2025 (1)
Chronic Recurrent Multifocal Osteomyelitis‐Like Paraneoplastic Syndrome as Initial Presentation of Nodular Sclerosis Classical Hodgkin Lymphoma
Hodgkin lymphoma (HL) presenting with initial skeletal symptoms as a paraneoplastic phenomenon is extremely rare. Herein, we report the case of a 26‐year‐old man with nodular sclerosis classical HL (NSCHL) who presented with low back pain as the initial symptom. Imaging studies were unremarkable except for right S1–S2 sacral marrow edema on MRI, and multiple biopsies showed only inflammatory changes, resulting in a tentative diagnosis of chronic recurrent multifocal osteomyelitis. Later in the course of the disease, after performing routine series of MRIs, lymphadenopathy was finally detected. Core biopsies of the axillary and pelvic lymph nodes subsequently confirmed the diagnosis of HL. Complete resolution of bone lesions was observed following lymphoma treatment. This case highlights the diagnostic challenges of HL, particularly when it presents with rare skeletal paraneoplastic manifestations.
- 1 January 2025
- Published by Wiley in Case Reports in Hematology
- Vol. 2025 (1)
Open AccessChronic Recurrent Multifocal Osteomyelitis‐Like Paraneoplastic Syndrome as Initial Presentation of Nodular Sclerosis Classical Hodgkin Lymphoma
Hodgkin lymphoma (HL) presenting with initial skeletal symptoms as a paraneoplastic phenomenon is extremely rare. Herein, we report the case of a 26‐year‐old man with nodular sclerosis classical HL (NSCHL) who presented with low back pain as the initial symptom. Imaging studies were unremarkable except for right S1–S2 sacral marrow edema on MRI, and multiple biopsies showed only inflammatory changes, resulting in a tentative diagnosis of chronic recurrent multifocal osteomyelitis. Later in the course of the disease, after performing routine series of MRIs, lymphadenopathy was finally detected. Core biopsies of the axillary and pelvic lymph nodes subsequently confirmed the diagnosis of HL. Complete resolution of bone lesions was observed following lymphoma treatment. This case highlights the diagnostic challenges of HL, particularly when it presents with rare skeletal paraneoplastic manifestations.
- 19 December 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 38 (2) , 100665
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis
- 19 December 2024
- Published by Elsevier in Laboratory Investigation
- Vol. 38 (2) , 100665
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis
- Open Access
- 13 August 2024
- Published by Wiley in Histopathology
- Vol. 86 (3) , 327-340
E‐cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes
Categorizing breast neoplasia as ductal or lobular is a daily exercise that relies on a combination of histologic and immunohistochemical tools. The historically robust link between loss of the E‐cadherin molecule and lobular neoplasia has rendered staining for E‐cadherin by immunohistochemistry a staple of this diagnostic process. Unfortunately, discordances between E‐cadherin expression and histomorphology, and variations in E‐cadherin staining patterns and intensities abound in clinical practice, but are often neglected in favour of a binary interpretation of the E‐cadherin result. In this article, we highlight the complexities of E‐cadherin expression through a review of the E‐cadherin protein and its associated gene (CDH1), the mechanisms leading to aberrant/absent E‐cadherin expression, and the implications of these factors on the reliability of the E‐cadherin immunohistochemical stain in the classification of ductal versus lobular mammary neoplasia.
- 13 August 2024
- Published by Wiley in Histopathology
- Vol. 86 (3) , 327-340
Open AccessE‐cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes
Categorizing breast neoplasia as ductal or lobular is a daily exercise that relies on a combination of histologic and immunohistochemical tools. The historically robust link between loss of the E‐cadherin molecule and lobular neoplasia has rendered staining for E‐cadherin by immunohistochemistry a staple of this diagnostic process. Unfortunately, discordances between E‐cadherin expression and histomorphology, and variations in E‐cadherin staining patterns and intensities abound in clinical practice, but are often neglected in favour of a binary interpretation of the E‐cadherin result. In this article, we highlight the complexities of E‐cadherin expression through a review of the E‐cadherin protein and its associated gene (CDH1), the mechanisms leading to aberrant/absent E‐cadherin expression, and the implications of these factors on the reliability of the E‐cadherin immunohistochemical stain in the classification of ductal versus lobular mammary neoplasia.
- Open Access
Macrophage-Based Therapeutic Strategies in Hematologic Malignancies
Macrophages are types of immune cells, with ambivalent functions in tumor growth, which depend on the specific environment in which they reside. Tumor-associated macrophages (TAMs) are a diverse population of immunosuppressive myeloid cells that play significant roles in several malignancies. TAM infiltration in malignancies has been linked to a poor prognosis and limited response to treatments, including those using checkpoint inhibitors. Understanding the precise mechanisms through which macrophages contribute to tumor growth is an active area of research as targeting these cells may offer potential therapeutic approaches for cancer treatment. Numerous investigations have focused on anti-TAM-based methods that try to eliminate, rewire, or target the functional mediators released by these cells. Considering the importance of these strategies in the reversion of tumor resistance to conventional therapies and immune modulatory vaccination could be an appealing approach for the immunosuppressive targeting of myeloid cells in the tumor microenvironment (TME). The combination of reprogramming and TAM depletion is a special feature of this approach compared to other clinical strategies. Thus, the present review aims to comprehensively overview the pleiotropic activities of TAMs and their involvement in various stages of cancer development as a potent drug target, with a focus on hematologic tumors.
Open AccessMacrophage-Based Therapeutic Strategies in Hematologic Malignancies
Macrophages are types of immune cells, with ambivalent functions in tumor growth, which depend on the specific environment in which they reside. Tumor-associated macrophages (TAMs) are a diverse population of immunosuppressive myeloid cells that play significant roles in several malignancies. TAM infiltration in malignancies has been linked to a poor prognosis and limited response to treatments, including those using checkpoint inhibitors. Understanding the precise mechanisms through which macrophages contribute to tumor growth is an active area of research as targeting these cells may offer potential therapeutic approaches for cancer treatment. Numerous investigations have focused on anti-TAM-based methods that try to eliminate, rewire, or target the functional mediators released by these cells. Considering the importance of these strategies in the reversion of tumor resistance to conventional therapies and immune modulatory vaccination could be an appealing approach for the immunosuppressive targeting of myeloid cells in the tumor microenvironment (TME). The combination of reprogramming and TAM depletion is a special feature of this approach compared to other clinical strategies. Thus, the present review aims to comprehensively overview the pleiotropic activities of TAMs and their involvement in various stages of cancer development as a potent drug target, with a focus on hematologic tumors.